Ming-Lung Yu
Overview
Explore the profile of Ming-Lung Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
535
Citations
6803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Irshad I, Alqahtani S, Ikejima K, Yu M, Romero-Gomez M, Eslam M
Ann Hepatol
. 2025 Mar;
:101896.
PMID: 40057035
Liver fibrosis is a progressive response to chronic liver diseases characterized by a wound-healing process that leads to the accumulation of fibrillary extracellular matrix (ECM) proteins in and around the...
2.
3.
Wang H, Zeng Y, Huang C, Chen C, Kuo H, Tseng K, et al.
J Formos Med Assoc
. 2025 Mar;
PMID: 40023754
Purpose: This study investigated whether Fibrosis-4 (FIB-4) score and its change can serve as predictors of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C (CHC) infection receiving direct-acting...
4.
Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C, et al.
Hepatol Int
. 2025 Feb;
PMID: 40016576
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association...
5.
Jang T, Zeng Y, Liang P, Wu C, Wei Y, Tsai P, et al.
Aliment Pharmacol Ther
. 2025 Feb;
PMID: 39968810
Background And Aims: Air pollution is associated with advanced liver fibrosis in patients with chronic liver diseases, including chronic hepatitis B (CHB). This study aimed to investigate the association between...
6.
Jang T, Zeng Y, Liang P, Wu C, Wei Y, Tsai P, et al.
J Chin Med Assoc
. 2025 Feb;
PMID: 39940072
Background: To investigate the association between air pollution and abnormal alanine aminotransferase levels in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs. Methods: This cross-sectional study enrolled 1,275 patients...
7.
Chen Y, Tsai P, Huang C, Chen C, Hung C, Chen C, et al.
J Formos Med Assoc
. 2025 Feb;
PMID: 39919992
Background/purpose: The risk of hepatocellular carcinoma (HCC) is increased in patients with chronic hepatitis C (CHC) and elevated alanine transaminase (ALT) levels. The association between HCC and ALT levels after...
8.
Razavi H, Waked I, Qureshi H, Kondili L, Duberg A, Aleman S, et al.
J Hepatol
. 2025 Feb;
PMID: 39914746
Background And Aims: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by...
9.
Lim Y, Yu M, Choi J, Chen C, Choi W, Kang W, et al.
Lancet Gastroenterol Hepatol
. 2025 Feb;
10(4):295-305.
PMID: 39914435
Background: Current guidelines for chronic hepatitis B recommend antiviral therapy for individuals with non-cirrhotic chronic hepatitis B only if they have significant liver fibrosis or elevated alanine aminotransferase (ALT) concentrations....
10.
Lee S, Yang S, Tsai P, Huang C, Chen C, Hung C, et al.
Clin Mol Hepatol
. 2025 Feb;
PMID: 39905837
Background & Aims: The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in BCLC stages B/C, remains largely...